Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development.
Summary
In obese mice, beta cell-derived cholecystokinin (CCK), not insulin, is a key driver of PDAC progression. Obesity expands immature β cells that reprogram via JNK/cJun to express CCK, reshaping peri-islet exocrine transcriptional states and fostering islet-proximal tumors.
Key Findings
- Beta cell CCK expression is necessary and sufficient to drive obesity-associated PDAC progression in mice, outperforming insulin as a correlate of tumorigenesis.
- Obesity induces expansion of postnatal immature β cells that adopt CCK expression via stress-responsive JNK/cJun signaling.
- CCK-dependent remodeling of peri-islet exocrine transcriptional states enhances islet-proximal tumor formation.
Clinical Implications
Although preclinical, findings suggest that modulating β-cell CCK or its stress-activated induction could mitigate PDAC risk/progression in obesity. They also support biomarker development assessing islet CCK activity near tumors.
Why It Matters
This study reframes endocrine–exocrine signaling in pancreatic cancer by identifying β cell CCK as a bona fide driver of obesity-associated PDAC. It opens tractable targets (CCK or upstream JNK/cJun) to disrupt tumor–islet crosstalk.
Limitations
- Preclinical mouse-focused evidence; limited direct validation in human PDAC tissues
- Potential context-specificity to obesity-associated tumorigenesis
Future Directions
Validate β-cell CCK axis in human PDAC, define therapeutic windows to target CCK or JNK/cJun without impairing islet function, and test combinatorial strategies with standard PDAC therapies.
Study Information
- Study Type
- Basic/mechanistic research
- Research Domain
- Pathophysiology
- Evidence Level
- IV - Preclinical mechanistic evidence from animal models and cellular analyses
- Study Design
- OTHER